X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA FRESENIUS KABI ONCO. NATCO PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 30.8 22.1 139.0% View Chart
P/BV x 23.3 3.1 748.5% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 NATCO PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
FRESENIUS KABI ONCO.
Mar-13
NATCO PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs877176 498.3%   
Low Rs42479 539.5%   
Sales per share (Unadj.) Rs223.437.7 592.9%  
Earnings per share (Unadj.) Rs31.15.1 610.0%  
Cash flow per share (Unadj.) Rs40.36.7 599.0%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs219.542.5 515.9%  
Shares outstanding (eoy) m33.07158.23 20.9%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.4 86.2%   
Avg P/E ratio x20.925.0 83.8%  
P/CF ratio (eoy) x16.118.9 85.3%  
Price / Book Value ratio x3.03.0 99.0%  
Dividend payout %16.10-   
Avg Mkt Cap Rs m21,50420,135 106.8%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m1,128703 160.4%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m7,3895,963 123.9%  
Other income Rs m16718 928.3%   
Total revenues Rs m7,5565,981 126.3%   
Gross profit Rs m1,7931,430 125.4%  
Depreciation Rs m304258 118.0%   
Interest Rs m366-26 -1,408.5%   
Profit before tax Rs m1,2901,216 106.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m309342 90.2%   
Profit after tax Rs m1,027806 127.5%  
Gross profit margin %24.324.0 101.2%  
Effective tax rate %23.928.1 85.1%   
Net profit margin %13.913.5 102.9%  
BALANCE SHEET DATA
Current assets Rs m3,6815,102 72.2%   
Current liabilities Rs m3,1232,385 130.9%   
Net working cap to sales %7.645.6 16.6%  
Current ratio x1.22.1 55.1%  
Inventory Days Days89150 59.6%  
Debtors Days Days59113 51.8%  
Net fixed assets Rs m7,6855,148 149.3%   
Share capital Rs m331158 209.0%   
"Free" reserves Rs m6,6706,556 101.7%   
Net worth Rs m7,2596,732 107.8%   
Long term debt Rs m955952 100.3%   
Total assets Rs m11,95710,388 115.1%  
Interest coverage x4.5-45.8 -9.9%   
Debt to equity ratio x0.10.1 93.0%  
Sales to assets ratio x0.60.6 107.7%   
Return on assets %11.77.5 155.2%  
Return on equity %14.212.0 118.2%  
Return on capital %20.714.6 141.9%  
Exports to sales %39.474.5 52.8%   
Imports to sales %5.724.8 23.0%   
Exports (fob) Rs m2,9084,441 65.5%   
Imports (cif) Rs m4211,477 28.5%   
Fx inflow Rs m3,4455,298 65.0%   
Fx outflow Rs m7031,772 39.7%   
Net fx Rs m2,7433,525 77.8%   
CASH FLOW
From Operations Rs m1,4401,274 113.0%  
From Investments Rs m-1,089-1,204 90.5%  
From Financial Activity Rs m-353-196 179.9%  
Net Cashflow Rs m-1-126 1.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 81.0 1.8%  
Indian inst/Mut Fund % 7.8 0.3 2,613.3%  
FIIs % 16.6 9.6 173.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 9.1 285.7%  
Shareholders   25,395 42,599 59.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  SHASUN PHARMA  

Compare NATCO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Jan 16, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS